BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

171 related articles for article (PubMed ID: 26754455)

  • 1. Using next-generation sequencing to determine potential molecularly guided therapy options for patients with resectable pancreatic adenocarcinoma.
    Wright GP; Chesla DW; Chung MH
    Am J Surg; 2016 Mar; 211(3):506-11. PubMed ID: 26754455
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Utility of Assessing the Number of Mutated KRAS, CDKN2A, TP53, and SMAD4 Genes Using a Targeted Deep Sequencing Assay as a Prognostic Biomarker for Pancreatic Cancer.
    Hayashi H; Kohno T; Ueno H; Hiraoka N; Kondo S; Saito M; Shimada Y; Ichikawa H; Kato M; Shibata T; Morizane C; Sakamoto Y; Shimada K; Komatsu Y; Sakamoto N; Okusaka T
    Pancreas; 2017 Mar; 46(3):335-340. PubMed ID: 28099251
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Targeted next generation sequencing of endoscopic ultrasound acquired cytology from ampullary and pancreatic adenocarcinoma has the potential to aid patient stratification for optimal therapy selection.
    Gleeson FC; Kerr SE; Kipp BR; Voss JS; Minot DM; Tu ZJ; Henry MR; Graham RP; Vasmatzis G; Cheville JC; Lazaridis KN; Levy MJ
    Oncotarget; 2016 Aug; 7(34):54526-54536. PubMed ID: 27203738
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Alterations in driver genes are predictive of survival in patients with resected pancreatic ductal adenocarcinoma.
    McIntyre CA; Lawrence SA; Richards AL; Chou JF; Wong W; Capanu M; Berger MF; Donoghue MTA; Yu KH; Varghese AM; Kelsen DP; Park W; Balachandran VP; Kingham TP; D'Angelica MI; Drebin JA; Jarnagin WR; Iacobuzio-Donahue CA; Allen PJ; O'Reilly EM
    Cancer; 2020 Sep; 126(17):3939-3949. PubMed ID: 32573775
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Immunohistochemically detected expression of 3 major genes (CDKN2A/p16, TP53, and SMAD4/DPC4) strongly predicts survival in patients with resectable pancreatic cancer.
    Oshima M; Okano K; Muraki S; Haba R; Maeba T; Suzuki Y; Yachida S
    Ann Surg; 2013 Aug; 258(2):336-46. PubMed ID: 23470568
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Combination of KRAS and SMAD4 mutations in formalin-fixed paraffin-embedded tissues as a biomarker for pancreatic cancer.
    Yokose T; Kitago M; Matsuda S; Sasaki Y; Masugi Y; Nakamura Y; Shinoda M; Yagi H; Abe Y; Oshima G; Hori S; Yusuke F; Nakano Y; Endo Y; Abe K; Tokino T; Kitagawa Y
    Cancer Sci; 2020 Jun; 111(6):2174-2182. PubMed ID: 32314446
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Clinical Effect of Driver Mutations of
    Gu Y; Ji Y; Jiang H; Qiu G
    Genet Test Mol Biomarkers; 2020 Dec; 24(12):777-788. PubMed ID: 33347393
    [No Abstract]   [Full Text] [Related]  

  • 8. Clinical next-generation sequencing successfully applied to fine-needle aspirations of pulmonary and pancreatic neoplasms.
    Young G; Wang K; He J; Otto G; Hawryluk M; Zwirco Z; Brennan T; Nahas M; Donahue A; Yelensky R; Lipson D; Sheehan CE; Boguniewicz AB; Stephens PJ; Miller VA; Ross JS
    Cancer Cytopathol; 2013 Dec; 121(12):688-94. PubMed ID: 23893923
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Usefulness of rapid on-site evaluation specimens from endoscopic ultrasound-guided fine-needle aspiration for cancer gene panel testing: A retrospective study.
    Ishizawa T; Makino N; Matsuda A; Kakizaki Y; Kobayashi T; Ikeda C; Sugahara S; Tsunoda M; Ueno Y
    PLoS One; 2020; 15(1):e0228565. PubMed ID: 31999789
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Long-term survivors of pancreatic adenocarcinoma show low rates of genetic alterations in KRAS, TP53 and SMAD4.
    Masetti M; Acquaviva G; Visani M; Tallini G; Fornelli A; Ragazzi M; Vasuri F; Grifoni D; Di Giacomo S; Fiorino S; Lombardi R; Tuminati D; Ravaioli M; Fabbri C; Bacchi-Reggiani ML; Pession A; Jovine E; de Biase D
    Cancer Biomark; 2018 Feb; 21(2):323-334. PubMed ID: 29103024
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Prognostic value of important driver gene mutations in patients with radical resection of pancreatic cancer].
    Shen J; Gao SZ; Wang H; Shi XH; Li B; Pan YQ; Shen S; Shao Z; Guo SW; Jin G
    Zhonghua Wai Ke Za Zhi; 2019 Nov; 57(11):840-847. PubMed ID: 31694133
    [No Abstract]   [Full Text] [Related]  

  • 12. Molecular alterations and targeted therapy in pancreatic ductal adenocarcinoma.
    Qian Y; Gong Y; Fan Z; Luo G; Huang Q; Deng S; Cheng H; Jin K; Ni Q; Yu X; Liu C
    J Hematol Oncol; 2020 Oct; 13(1):130. PubMed ID: 33008426
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Genomic sequencing of key genes in mouse pancreatic cancer cells.
    Wang Y; Zhang Y; Yang J; Ni X; Liu S; Li Z; Hodges SE; Fisher WE; Brunicardi FC; Gibbs RA; Gingras MC; Li M
    Curr Mol Med; 2012 Mar; 12(3):331-41. PubMed ID: 22208613
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Targeted next-generation sequencing of commonly mutated genes in esophageal adenocarcinoma patients with long-term survival.
    Visser E; Franken IA; Brosens LAA; de Leng WWJ; Strengman E; Offerhaus JA; Ruurda JP; van Hillegersberg R
    Dis Esophagus; 2017 Sep; 30(9):1-8. PubMed ID: 28859360
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Next-Generation Sequencing and Fluorescence in Situ Hybridization Have Comparable Performance Characteristics in the Analysis of Pancreaticobiliary Brushings for Malignancy.
    Dudley JC; Zheng Z; McDonald T; Le LP; Dias-Santagata D; Borger D; Batten J; Vernovsky K; Sweeney B; Arpin RN; Brugge WR; Forcione DG; Pitman MB; Iafrate AJ
    J Mol Diagn; 2016 Jan; 18(1):124-30. PubMed ID: 26596524
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Impact of epidermal growth factor receptor (EGFR) kinase mutations, EGFR gene amplifications, and KRAS mutations on survival of pancreatic adenocarcinoma.
    Lee J; Jang KT; Ki CS; Lim T; Park YS; Lim HY; Choi DW; Kang WK; Park K; Park JO
    Cancer; 2007 Apr; 109(8):1561-9. PubMed ID: 17354229
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cytomorphological identification of advanced pulmonary adenocarcinoma harboring KRAS mutation in lymph node fine-needle aspiration specimens: Comparative investigation of adenocarcinoma with KRAS and EGFR mutations.
    Song DH; Lee B; Shin Y; Choi IH; Ha SY; Lee JJ; Hong ME; Choi YL; Han J; Um SW
    Diagn Cytopathol; 2015 Jul; 43(7):539-44. PubMed ID: 25427298
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Deciphering Genetic Alterations of Taiwanese Patients with Pancreatic Adenocarcinoma through Targeted Sequencing.
    Huang CC; Liu CY; Huang CJ; Hsu YC; Lien HH; Wong JU; Tai FC; Ku WH; Hung CF; Lin JT; Huang CS; Chiang HS
    Int J Mol Sci; 2022 Jan; 23(3):. PubMed ID: 35163506
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Genetic aspects of pancreatic cancer].
    Grigor'eva IN; Efimova OV; Suvorova TS; Tov NL
    Eksp Klin Gastroenterol; 2014; (10):70-6. PubMed ID: 25911935
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Characterization of pancreatic ductal adenocarcinoma using whole transcriptome sequencing and copy number analysis by single-nucleotide polymorphism array.
    Di Marco M; Astolfi A; Grassi E; Vecchiarelli S; Macchini M; Indio V; Casadei R; Ricci C; D'Ambra M; Taffurelli G; Serra C; Ercolani G; Santini D; D'Errico A; Pinna AD; Minni F; Durante S; Martella LR; Biasco G
    Mol Med Rep; 2015 Nov; 12(5):7479-84. PubMed ID: 26397140
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.